Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Szu-Chi LiaoGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0003-2744-363X
Kohei KanoGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-0223-5781
Sadhna PhanseDepartment of Biochemistry, University of Regina, Regina, Saskatchewan, Canada.ORCID 0000-0001-6306-0551
Mai NguyenGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0003-3550-7728
Elyssa MargolisWeill Institute for Neurosciences, Department of Neurology, and Kavli Institute for Fundamental Neuroscience, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-8777-302X
YuHong FuAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.ORCID 0000-0003-4539-2039
Jonathan X MengGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-4315-3483
Mohamed Taha MoutaoufikDepartment of Biochemistry, University of Regina, Regina, Saskatchewan, Canada.ORCID 0000-0002-2013-1601
Zac ChattertonAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.ORCID 0000-0002-6683-1400
Tatiana SacconDepartment of Biochemistry, University of Regina, Regina, Saskatchewan, Canada.ORCID 0000-0001-5328-4922
Kirsten BroderickDepartment of Biochemistry, University of Regina, Regina, Saskatchewan, Canada.
Hiroyuki AokiDepartment of Biochemistry, University of Regina, Regina, Saskatchewan, Canada.ORCID 0009-0005-9143-086X
Jeffrey SimmsGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.
Felicia Xaveria SutejaAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.
Yoshitaka SeiGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-4725-8725
Eric J HuangWeill Institute for Neurosciences, Department of Neurology, and Kavli Institute for Fundamental Neuroscience, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-5381-3801
Kevin McAvoyFeil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-0025-1921
Giovanni ManfrediFeil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.
Glenda HallidayAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA.ORCID 0000-0003-0422-8398
Mohan BabuDepartment of Biochemistry, University of Regina, Regina, Saskatchewan, Canada.ORCID 0000-0003-4118-6406
Ken NakamuraGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA, USA.ORCID 0000-0002-9192-182X
Funding
UCSF IRACDA Scholars ProgramK12GM081266 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Raymond M. Esquerra, HOLLY A. INGRAHAM · 2007 to 2026
$19.4M
Mitochondrial Integrated Stress Response in Neurological DiseasesR35NS122209 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Giovanni Manfredi · 2021 to 2026
$6.6M
Defining Strategies to Target Energy Failure in Metabolically Vulnerable Human CellsR01AG065428 · NIA · J. DAVID GLADSTONE INSTITUTES · PI NAKAMURA, KEN · 2020 to 2024
$3.7M
Understand and probing disrupted glucose metabolism in Alzheimer's diseaseRF1AG064170 · NIA · J. DAVID GLADSTONE INSTITUTES · PI CHAUMEIL, MYRIAM MARIANNE, NAKAMURA, KEN · 2019 to 2019
$3.6M
EXTRAMULAR RESEARCH FACILITIES CONSTRUCTIONC06RR018928 · NCRR · J. DAVID GLADSTONE INSTITUTES · PI MAHLEY, ROBERT W. · 2003 to 2003
Mitochondrial dysfunction is a hallmark of Parkinson's disease (PD), but the mechanisms by which it drives autosomal dominant and idiopathic forms of PD remain unclear. To investigate this, we generated and performed a comprehensive phenotypic analysis of a knock-in mouse model carrying the T61I mutation in the mitochondrial protein CHCHD2 (coiled-coil-helix-coiled-coil-helix domain-containing 2), which causes late-onset symptoms indistinguishable from idiopathic PD. We observed pronounced mitochondrial disruption in substantia nigra dopaminergic neurons, including distorted ultrastructure and CHCHD2 aggregation, as well as disrupted mitochondrial protein-protein interactions in brain lysates. These abnormalities were associated with a whole-body metabolic shift toward glycolysis, elevated mitochondrial reactive oxygen species (ROS), and progressive accumulation of aggregated α-synuclein. In idiopathic PD,
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
CHCHD2 mutant mice link mitochondrial deficits to PD pathophysiology. · full record | Socratic